zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresíva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
bonaxon
egis pharmaceuticals plc, maďarsko - fingolimod - 59 - immunopraeparata
chantico 0,5 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - fingolimod - 59 - immunopraeparata
fimodigo 0,5 mg
vipharm s.a., poľsko - fingolimod - 59 - immunopraeparata
fingolimod stada 0,5 mg tvrdé kapsuly
stada arzneimittel ag, nemecko - fingolimod - 59 - immunopraeparata
fingolimod zentiva 0,5 mg
zentiva, k.s., Česká republika - fingolimod - 59 - immunopraeparata
efigalo 0,5 mg tvrdé kapsuly
krka, d.d., novo mesto, slovinsko - fingolimod - 59 - immunopraeparata
fingolimod glenmark 0,5 mg
glenmark pharmaceuticals s.r.o., Česká republika - fingolimod - 59 - immunopraeparata
golpimec 0,5 mg tvrdé kapsuly
neuraxpharm bohemia s.r.o., Česká republika - fingolimod - 59 - immunopraeparata
lognif 0,5 mg tvrdé kapsuly
teva pharmaceuticals slovakia s.r.o., slovensko - fingolimod - 59 - immunopraeparata